Scilex Holding Company $SCLX Shares Bought by Goldman Sachs Group Inc.

Key Points

• Goldman Sachs Group Inc. increased its stake in Scilex Holding Company by 31.2%, now holding 136,352 shares valued at approximately $34,000.
• Scilex's stock is currently trading down 26.1%, with a twelve-month high of $39.90 and a low of $3.60.
• The company reported a quarterly EPS of ($7.42), missing expectations by ($2.87), with revenues of $9.90 million, significantly below analyst estimates.

Goldman Sachs Group Inc. grew its position in Scilex Holding Company (NASDAQ:SCLX - Free Report) by 31.2% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 136,352 shares of the company's stock after purchasing an additional 32,449 shares during the period. Goldman Sachs Group Inc. owned approximately 1.96% of Scilex worth $34,000 at the end of the most recent quarter.

Separately, Jane Street Group LLC lifted its holdings in shares of Scilex by 965.8% during the fourth quarter. Jane Street Group LLC now owns 321,480 shares of the company's stock worth $137,000 after purchasing an additional 291,316 shares during the period. Institutional investors own 69.67% of the company's stock.

Scilex Trading Down 26.1%

Shares of NASDAQ:SCLX opened at $19.68 on Wednesday. Scilex Holding Company has a twelve month low of $3.60 and a twelve month high of $39.90. The company has a market cap of $136.97 million, a PE ratio of -0.68 and a beta of 1.34. The company's 50 day moving average is $19.89 and its 200 day moving average is $11.07.

Scilex (NASDAQ:SCLX - Get Free Report) last announced its quarterly earnings data on Wednesday, August 13th. The company reported ($7.42) EPS for the quarter, missing the consensus estimate of ($4.55) by ($2.87). The business had revenue of $9.90 million for the quarter, compared to analyst estimates of $26.25 million. Equities research analysts predict that Scilex Holding Company will post -0.57 earnings per share for the current fiscal year.

Scilex Profile

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.

Want to see what other hedge funds are holding SCLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Scilex Holding Company (NASDAQ:SCLX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.